Pharmacyte Biotech Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
PMCB Nasdaq 2833 http://pharmacyte.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pharmacyte Biotech Inc

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING - Jun 23rd, 2022 1:00 pm
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value - Jun 15th, 2022 12:30 pm
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego - Jun 13th, 2022 12:30 pm
IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS - Jun 9th, 2022 1:00 pm
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value - Jun 8th, 2022 12:30 pm
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program - Jun 2nd, 2022 1:00 pm
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites - May 23rd, 2022 1:00 pm
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes - Apr 27th, 2022 1:00 pm
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements - Apr 19th, 2022 1:00 pm
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial - Apr 13th, 2022 1:00 pm
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors - Apr 5th, 2022 1:00 pm
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate - Mar 22nd, 2022 1:00 pm
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights - Mar 16th, 2022 1:00 pm
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration - Feb 22nd, 2022 2:00 pm
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA - Feb 14th, 2022 2:00 pm
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference - Jan 6th, 2022 2:00 pm
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells - Jan 4th, 2022 2:00 pm
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study - Dec 28th, 2021 2:00 pm
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights - Dec 15th, 2021 2:00 pm
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay - Dec 8th, 2021 3:16 pm